Transaction DateRecipientSharesTypePriceValue
31st December 2020Advisory Partners Lp Ardsley50,000Other acquisition or disposition$1.26$63,000.00
31st December 2020Advisory Partners Lp Ardsley50,000Other acquisition or disposition$1.26$63,000.00
15th December 2020Ag Science Llc Ospraie9,476,221Exercise of derivative$0.75$7,107,165.75
14th December 2020Advisory Partners Lp Ardsley1,648,037Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.75$1,236,027.75
15th September 2020Ag Science Llc Ospraie1,974,213Exercise of derivative$0.75$1,480,659.75
15th September 2020Advisory Partners Lp Ardsley343,341Exercise of derivative$0.00
18th August 2020Advisory Partners Lp Ardsley2,300,000Open or private sale$6.00$13,800,000.00
18th August 2020Advisory Partners Lp Ardsley1,000,000Open or private sale$6.00$6,000,000.00
6th August 2020Advisory Partners Lp Ardsley12,500Open or private sale$6.77$84,625.00
5th August 2020Advisory Partners Lp Ardsley25,000Open or private sale$7.10$177,500.00
Marrone Bio Innovations
Marrone Bio Innovations logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Marrone Bio Innovations, Inc. was founded by Pamela G. Marrone on June 15, 2006. Its brand includes regalia, bio-tam, grandevo, venerate and majestene.

Ticker: MBII
Sector: Basic Materials
Industry: Agricultural Inputs
SEC Central Index Key (CIK): 1441693
Employees: 113
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $10 M (0%)
Inventory, Net: $6 M (0%)
Assets, Current: $29 M (35%)
Property, Plant and Equipment, Net: $13 M (-1%)
Other Assets, Noncurrent: $891 Th (-11%)
Assets: $78 M (7%)
Accounts Payable, Current: $1 M (-69%)
Accrued Liabilities, Current: $14 M (0%)
Liabilities, Current: $26 M (22%)
Long-term Debt, Excluding Current Maturities: $11 M (-3%)
Other Liabilities, Noncurrent: $2 M (-21%)
Liabilities: $52 M (6%)
Common Stock, Value, Issued: $1 Th (0%)
Common Stock, Shares, Issued: $149 Th (7%)
Retained Earnings (Accumulated Deficit): $331 M (0%)
Stockholders' Equity (Parent): $26 M (0%)
Liabilities and Equity: $78 M (7%)
Revenue: $12 M (-44%)
Gross Margin: $7 M (-42%)
Research and Development: $2 M (-38%)
Operating Income/Loss: $2 M (-73%)
Other Income, net: $818 Th (-61%)
Provision for income taxes: $46 Th (-42%)